Am Pharma

Tripterygium wilfordii Hook F has significant anti-inflammatory and immunosuppressive properties and is widely used for treating autoimmune and inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus, and kidney disease, 

riptolide and celastrol are predominantly active natural products isolated from the medicinal plant Tripterygium wilfordii Hook F. These compounds exhibit similar pharmacological activities, including anti-cancer, anti-inflammation, anti-obesity, and anti-diabetic activities.

Infimab is a brand name for an infliximab injection, which is a biologic drug that is commonly used for treating various autoimmune diseases. The 100 mg Infimab (Infliximab) injection is used for the following conditions:

1. Rheumatoid Arthritis (RA):

   • Infliximab is used to treat rheumatoid arthritis, an autoimmune disease where the immune system attacks the joints, causing inflammation, pain, and potential joint damage. It is often used in combination with methotrexate to help reduce symptoms, prevent joint damage, and improve function.

2. Inflammatory Bowel Diseases (IBD):

   • Crohn's Disease: Infliximab is used to treat Crohn's disease, a chronic inflammatory bowel disease (IBD) that affects the digestive tract, causing symptoms such as abdominal pain, diarrhea, and weight loss.
   • Ulcerative Colitis: It is also used for treating ulcerative colitis, another type of IBD that primarily affects the colon and rectum, causing symptoms like bloody diarrhea, abdominal cramps, and urgency.

3. Ankylosing Spondylitis:

   • Infliximab is used in the treatment of ankylosing spondylitis, a type of arthritis that affects the spine and large joints, causing stiffness and pain. It helps reduce inflammation and improve mobility in affected areas.

4. Psoriatic Arthritis:

   • Infliximab is also used to treat psoriatic arthritis, a form of arthritis associated with the skin condition psoriasis. It helps reduce joint inflammation and skin lesions.

5. Plaque Psoriasis:

   • Infliximab is used for plaque psoriasis, a chronic autoimmune skin condition characterized by red, scaly patches. It helps reduce the severity of skin lesions.

6. Other Autoimmune Diseases:

   • Infliximab may also be used off-label for other autoimmune conditions, such as juvenile idiopathic arthritis (JIA) or systemic lupus erythematosus (SLE), depending on a healthcare provider’s recommendation.

Infliximab is a monoclonal antibody that works by targeting and inhibiting tumor necrosis factor-alpha (TNF-alpha), a protein involved in the inflammatory response in the body. By blocking TNF-alpha, Infliximab reduces inflammation and helps control the immune system’s abnormal response, which is responsible for many of the symptoms of autoimmune diseases.

• Infliximab (Infimab) is typically administered via intravenous (IV) infusion in a healthcare setting.
• The 100 mg dose is typically part of a larger infusion regimen, with doses adjusted based on the specific condition being treated. The exact dosing schedule varies depending on the condition and the patient’s response to treatment.
• The initial dose may be followed by additional infusions at specified intervals, such as every 6 to 8 weeks for maintenance therapy.

• Inflammatory Conditions: Rheumatoid arthritis, lupus, and inflammatory bowel diseases.
• Allergic Disorders: Severe allergic reactions or asthma.
• Neuromuscular Disorders: Approved for the treatment of Duchenne Muscular Dystrophy (DMD).
• Other Uses: Skin conditions, organ transplantation, and various autoimmune diseases.

1 mg/mL Tofacitinib Tablets are used in the treatment of several autoimmune and inflammatory conditions. Tofacitinib is an oral Janus kinase (JAK) inhibitor that works by inhibiting specific enzymes that contribute to the inflammatory processes in the body.

1. Rheumatoid Arthritis (RA):

   • Tofacitinib is commonly used to treat rheumatoid arthritis in adults. It helps reduce the symptoms of this chronic inflammatory disease, such as joint pain, swelling, and stiffness. By inhibiting the JAK enzymes, Tofacitinib reduces the activity of the immune system that leads to inflammation in the joints, ultimately controlling disease progression and improving function.

2. Psoriatic Arthritis (PsA):

   • Tofacitinib is also prescribed for psoriatic arthritis, a condition that causes joint inflammation and skin issues (psoriasis). The drug helps reduce inflammation, relieves pain, and improves joint function in people with PsA, thereby improving the quality of life.

3. Ulcerative Colitis (UC):

   • Tofacitinib is used to treat ulcerative colitis, an inflammatory bowel disease that causes chronic inflammation in the colon. By suppressing the immune system’s inflammatory response, Tofacitinib helps reduce symptoms such as abdominal pain, diarrhea, and rectal bleeding in patients with moderate to severe UC. It can help induce and maintain remission.

4. Moderate to Severe Atopic Dermatitis (Eczema):

   • In some cases, Tofacitinib is used to treat atopic dermatitis (eczema), particularly for patients with moderate to severe forms of the condition who do not respond well to other treatments. It helps reduce inflammation and itching associated with eczema.

• Tofacitinib is a Janus kinase (JAK) inhibitor that blocks the activity of specific enzymes (JAK1, JAK2, JAK3, and Tyk2) that are involved in the signaling pathways of several pro-inflammatory cytokines. These cytokines play a role in immune system activation and the inflammatory response in autoimmune diseases. By inhibiting these enzymes, Tofacitinib helps to reduce inflammation and control the immune system’s abnormal response.

• Tofacitinib tablets are typically taken orally, with or without food. The dosage depends on the condition being treated:
  • For rheumatoid arthritis, the usual dose is 5 mg twice a day.
  • For psoriatic arthritis, the starting dose is often 5 mg twice a day.
  • For ulcerative colitis, the initial dose can be 10 mg twice a day, which may be reduced to a maintenance dose after the disease is controlled.
  • For atopic dermatitis, the dose is generally 5 mg twice a day, depending on individual factors.
  The exact dosage and schedule will depend on your doctor's recommendations based on your condition and response to treatment.

• The most common side effects of Tofacitinib include:

  • Upper respiratory infections (cold-like symptoms)
  • Headaches
  • Diarrhea
  • Nausea
  • Increased blood pressure
  • Rash

Tofacitinib (brand name Jaknat) is an oral Janus kinase (JAK) inhibitor used to treat several autoimmune and inflammatory conditions. Here are the main uses for Tofacitinib tablets:

• Tofacitinib is used to treat moderate to severe rheumatoid arthritis (RA) in adults who have not responded well to methotrexate or other disease-modifying antirheumatic drugs (DMARDs). It helps reduce inflammation, pain, and damage caused by the immune system attacking the joints.

• Tofacitinib is prescribed to treat psoriatic arthritis, a condition that causes joint pain, swelling, and skin patches. It is used in cases where other treatments are not effective.

• Tofacitinib is used to treat moderate to severe ulcerative colitis, an inflammatory bowel disease (IBD) that causes inflammation and ulcers in the colon and rectum. It helps manage symptoms such as abdominal pain, diarrhea, and rectal bleeding.

• Tofacitinib can be used to treat atopic dermatitis (eczema), particularly in cases that do not respond to topical therapies or other systemic treatments. It helps control the overactive immune response that causes skin inflammation and itching.

Tofacitinib inhibits Janus kinases (JAKs), which are enzymes involved in the signaling pathways that regulate immune cell function. By blocking JAKs, tofacitinib helps reduce the activity of the immune system, thereby reducing inflammation and symptoms associated with autoimmune diseases.

• Monitoring: Due to its effect on the immune system, tofacitinib can increase the risk of infections, including serious ones like tuberculosis. Regular monitoring of blood counts, liver function, and lipid levels is necessary during treatment.
• Side Effects: Common side effects may include upper respiratory infections, headache, diarrhea, high blood pressure, and liver enzyme abnormalities. Severe side effects include an increased risk of certain cancers and blood clots.

Tofacitinib should be taken under the guidance of a healthcare provider, and it may be used alongside other treatments depending on the condition being treated.

• 15, 20, 50 mg

Tofajak IN (Tofacitinib) Tablets are used for the treatment of several autoimmune and inflammatory conditions. Tofacitinib is a Janus kinase (JAK) inhibitor that works by blocking certain enzymes involved in the inflammatory process. It is used in conditions where the immune system is overactive and causes inflammation in the body.

1. Rheumatoid Arthritis (RA):

   • Tofacitinib is primarily used for rheumatoid arthritis (RA), an autoimmune condition where the immune system attacks the joints, leading to inflammation, pain, and damage. Tofacitinib helps reduce these symptoms by inhibiting the JAK enzymes that are involved in the inflammatory response.
   • It is often used in moderate to severe rheumatoid arthritis when other disease-modifying antirheumatic drugs (DMARDs), like methotrexate, have not been effective.

2. Psoriatic Arthritis (PsA):

   • Tofacitinib is used for the treatment of psoriatic arthritis, a condition that causes joint inflammation and is often associated with the skin condition psoriasis. Tofacitinib helps control the inflammation and improves joint function in patients with psoriatic arthritis.
   • It is commonly prescribed for active psoriatic arthritis when other medications have not provided sufficient relief.

3. Ulcerative Colitis (UC):

   • Tofacitinib is indicated for moderate to severe ulcerative colitis in adults. Ulcerative colitis is an inflammatory bowel disease that causes inflammation and ulcers in the colon. Tofacitinib helps reduce inflammation, improves symptoms like diarrhea, rectal bleeding, and abdominal pain, and can help induce and maintain remission in people with UC.

4. Atopic Dermatitis (Eczema):

   • Tofacitinib is sometimes used in the treatment of moderate to severe atopic dermatitis (eczema), especially for patients who do not respond well to topical treatments. It helps reduce inflammation, itching, and skin lesions associated with eczema.

• Tofacitinib is a JAK inhibitor. JAK enzymes are involved in the signaling pathways of various pro-inflammatory cytokines (proteins that mediate inflammation). By inhibiting these enzymes, Tofacitinib reduces the activity of the immune system that causes inflammation, helping to control the symptoms of autoimmune diseases.
• Specifically, Tofacitinib blocks JAK1, JAK2, JAK3, and TYK2 enzymes, which are involved in the immune response. This inhibition reduces the production of inflammatory substances in the body.

• Tofacitinib Tablets (Tofajak IN) are taken orally, typically twice a day. The usual starting dose for rheumatoid arthritis and psoriatic arthritis is 5 mg twice daily, while for ulcerative colitis, it is 10 mg twice a day for a short period, followed by a reduced maintenance dose of 5 mg or 10 mg daily.
• The dose may be adjusted based on the patient’s response to the medication and tolerability.

Common side effects of Tofajak IN (Tofacitinib) include:

• Upper respiratory infections (cold-like symptoms)
• Headache
• Diarrhea
• Nausea
• Increased blood pressure
• Rash